BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Alam I, Brown K, Donovan C, Forlenza J, Lauwers K, Mah'moud MA, Manch R, Mohanty SR, Prabhakar A, Reindollar R, DeMasi R, Slim J, Tandon N, Villadiego S, Naggie S. Real-World Effectiveness of Simeprevir-containing Regimens Among Patients With Chronic Hepatitis C Virus: The SONET Study. Open Forum Infect Dis 2017;4:ofw258. [PMID: 28480251 DOI: 10.1093/ofid/ofw258] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Gayam V, Tiongson B, Khalid M, Mandal AK, Mukhtar O, Gill A, Garlapati P, Shrestha B, Khalid M, Chakraborty S, Guss D, Sherigar J, Mansour M, Mohanty S. Sofosbuvir based regimens in the treatment of chronic hepatitis C genotype 1 infection in African-American patients: a community-based retrospective cohort study. Eur J Gastroenterol Hepatol 2018;30:1200-7. [PMID: 30096090 DOI: 10.1097/MEG.0000000000001233] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
2 Tran AN, Sachdev R, Fricker ZP, Leber M, Zahorian T, Shah B, Nunes DP, Long MT. Intensive Pharmacy Care Improves Outcomes of Hepatitis C Treatment in a Vulnerable Patient Population at a Safety-Net Hospital. Dig Dis Sci 2018;63:3241-9. [PMID: 30078116 DOI: 10.1007/s10620-018-5231-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
3 Pott-Junior H, Bricks G, Grandi G, Figueiredo Senise J, Castelo Filho A. Sofosbuvir in combination with daclatasvir or simeprevir for 12 weeks in noncirrhotic subjects chronically infected with hepatitis C virus genotype 1: a randomized clinical trial. Clin Microbiol Infect 2019;25:365-71. [PMID: 29906601 DOI: 10.1016/j.cmi.2018.06.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Marra F, Höner Zu Siederdissen C, Khoo S, Back D, Schlag M, Ouwerkerk-Mahadevan S, Bicer C, Lonjon-Domanec I, Jessner W, Beumont-Mauviel M, Kalmeijer R, Cornberg M. Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications. Br J Clin Pharmacol 2018;84:961-71. [PMID: 29345798 DOI: 10.1111/bcp.13519] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
5 Cárdaba-García ME, Abad-Lecha E, Calleja-Hernández MÁ. Effectiveness of direct-acting antiviral drugs against hepatitis C virus: predictive factors of response to the treatment. Libyan J Med 2021;16:1949797. [PMID: 34308801 DOI: 10.1080/19932820.2021.1949797] [Reference Citation Analysis]
6 Gaeta GB, Aghemo A, Menzaghi B, D'Offizi G, Giorgini A, Hasson H, Brancaccio G, Palma M, Termini R; STIly Study Group. Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy: The STIly observational study. Medicine (Baltimore) 2018;97:e11307. [PMID: 29979400 DOI: 10.1097/MD.0000000000011307] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
7 Laurain A, Metivier S, Haour G, Larrey D, Dorival C, Hezode C, Zoulim F, Marcellin P, Bourliere M, Zarski JP, Thabut D, Alric L, Ganne-Carrie N, Cales P, Bronowicki JP, Riachi G, Geist C, Causse X, Abergel A, Chazouilleres O, Mathurin P, Guyader D, Samuel D, Tran A, Loustaud-Ratti V, Petrov-Sanchez V, Diallo A, Luzivika-Nzinga C, Fontaine H, Carrat F, Pol S; ANRS/AFEF HEPATHER study group. Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort. BMC Infect Dis 2019;19:300. [PMID: 30940090 DOI: 10.1186/s12879-019-3923-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]